JPWO2020163365A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020163365A5 JPWO2020163365A5 JP2021545400A JP2021545400A JPWO2020163365A5 JP WO2020163365 A5 JPWO2020163365 A5 JP WO2020163365A5 JP 2021545400 A JP2021545400 A JP 2021545400A JP 2021545400 A JP2021545400 A JP 2021545400A JP WO2020163365 A5 JPWO2020163365 A5 JP WO2020163365A5
- Authority
- JP
- Japan
- Prior art keywords
- zc3h12a
- socs1
- optionally
- immune effector
- targeting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000623 proteins and genes Proteins 0.000 claims 115
- 210000004027 cell Anatomy 0.000 claims 54
- 230000008685 targeting Effects 0.000 claims 47
- 239000012642 immune effector Substances 0.000 claims 45
- 229940121354 immunomodulator Drugs 0.000 claims 45
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 43
- 102100023882 Endoribonuclease ZC3H12A Human genes 0.000 claims 42
- 101000976212 Homo sapiens Endoribonuclease ZC3H12A Proteins 0.000 claims 42
- 101150045565 Socs1 gene Proteins 0.000 claims 42
- 102000058018 Suppressor of Cytokine Signaling 1 Human genes 0.000 claims 42
- 108700027336 Suppressor of Cytokine Signaling 1 Proteins 0.000 claims 42
- 108020005004 Guide RNA Proteins 0.000 claims 38
- 102000004169 proteins and genes Human genes 0.000 claims 36
- 230000001105 regulatory effect Effects 0.000 claims 32
- 150000007523 nucleic acids Chemical class 0.000 claims 27
- 108091027967 Small hairpin RNA Proteins 0.000 claims 19
- 239000004055 small Interfering RNA Substances 0.000 claims 19
- 108020004459 Small interfering RNA Proteins 0.000 claims 17
- 239000002924 silencing RNA Substances 0.000 claims 17
- 108020004707 nucleic acids Proteins 0.000 claims 15
- 102000039446 nucleic acids Human genes 0.000 claims 15
- 239000002773 nucleotide Substances 0.000 claims 12
- 125000003729 nucleotide group Chemical group 0.000 claims 12
- 101001135572 Homo sapiens Tyrosine-protein phosphatase non-receptor type 2 Proteins 0.000 claims 11
- 206010028980 Neoplasm Diseases 0.000 claims 11
- 102100033141 Tyrosine-protein phosphatase non-receptor type 2 Human genes 0.000 claims 11
- 230000002255 enzymatic effect Effects 0.000 claims 11
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims 8
- 238000000034 method Methods 0.000 claims 8
- 239000011701 zinc Substances 0.000 claims 8
- 229910052725 zinc Inorganic materials 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 7
- 230000000295 complement effect Effects 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 239000012636 effector Substances 0.000 claims 7
- 230000000415 inactivating effect Effects 0.000 claims 7
- 239000003112 inhibitor Substances 0.000 claims 7
- 230000035772 mutation Effects 0.000 claims 7
- 239000000427 antigen Substances 0.000 claims 5
- 102000036639 antigens Human genes 0.000 claims 5
- 108091007433 antigens Proteins 0.000 claims 5
- 102100035880 Max-interacting protein 1 Human genes 0.000 claims 4
- 101710112905 Max-interacting protein 1 Proteins 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 230000001939 inductive effect Effects 0.000 claims 4
- 102000040430 polynucleotide Human genes 0.000 claims 4
- 108091033319 polynucleotide Proteins 0.000 claims 4
- 239000002157 polynucleotide Substances 0.000 claims 4
- 230000003007 single stranded DNA break Effects 0.000 claims 4
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 3
- 108010042407 Endonucleases Proteins 0.000 claims 3
- 102000004533 Endonucleases Human genes 0.000 claims 3
- 108091008874 T cell receptors Proteins 0.000 claims 3
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 108091008915 immune receptors Proteins 0.000 claims 3
- 102000027596 immune receptors Human genes 0.000 claims 3
- 108020005544 Antisense RNA Proteins 0.000 claims 2
- 108091033409 CRISPR Proteins 0.000 claims 2
- 108010008532 Deoxyribonuclease I Proteins 0.000 claims 2
- 102000007260 Deoxyribonuclease I Human genes 0.000 claims 2
- 108010072388 Methyl-CpG-Binding Protein 2 Proteins 0.000 claims 2
- 102100039124 Methyl-CpG-binding protein 2 Human genes 0.000 claims 2
- 108700011259 MicroRNAs Proteins 0.000 claims 2
- 102000004389 Ribonucleoproteins Human genes 0.000 claims 2
- 108010081734 Ribonucleoproteins Proteins 0.000 claims 2
- 238000010459 TALEN Methods 0.000 claims 2
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 claims 2
- 108010017070 Zinc Finger Nucleases Proteins 0.000 claims 2
- 239000003184 complementary RNA Substances 0.000 claims 2
- 230000037430 deletion Effects 0.000 claims 2
- 238000012217 deletion Methods 0.000 claims 2
- 230000003308 immunostimulating effect Effects 0.000 claims 2
- 239000002679 microRNA Substances 0.000 claims 2
- 230000018883 protein targeting Effects 0.000 claims 2
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 claims 2
- 102000019034 Chemokines Human genes 0.000 claims 1
- 108010012236 Chemokines Proteins 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 101710163270 Nuclease Proteins 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 108700019146 Transgenes Proteins 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 claims 1
- 210000000170 cell membrane Anatomy 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 230000003833 cell viability Effects 0.000 claims 1
- 230000003013 cytotoxicity Effects 0.000 claims 1
- 231100000135 cytotoxicity Toxicity 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 238000004520 electroporation Methods 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 231100000221 frame shift mutation induction Toxicity 0.000 claims 1
- 230000037433 frameshift Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000004068 intracellular signaling Effects 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000037841 lung tumor Diseases 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 210000000581 natural killer T-cell Anatomy 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 229920001228 polyisocyanate Polymers 0.000 claims 1
- 239000005056 polyisocyanate Substances 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 230000002103 transcriptional effect Effects 0.000 claims 1
- 238000010361 transduction Methods 0.000 claims 1
- 230000026683 transduction Effects 0.000 claims 1
- 238000001890 transfection Methods 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024098698A JP2024111155A (ja) | 2019-02-04 | 2024-06-19 | 免疫療法の改善のための遺伝子標的の組み合わせ |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962800999P | 2019-02-04 | 2019-02-04 | |
| US62/800,999 | 2019-02-04 | ||
| US201962818677P | 2019-03-14 | 2019-03-14 | |
| US62/818,677 | 2019-03-14 | ||
| PCT/US2020/016623 WO2020163365A2 (en) | 2019-02-04 | 2020-02-04 | Combination gene targets for improved immunotherapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024098698A Division JP2024111155A (ja) | 2019-02-04 | 2024-06-19 | 免疫療法の改善のための遺伝子標的の組み合わせ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022519595A JP2022519595A (ja) | 2022-03-24 |
| JPWO2020163365A5 true JPWO2020163365A5 (enExample) | 2023-02-10 |
Family
ID=71947815
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021545400A Pending JP2022519595A (ja) | 2019-02-04 | 2020-02-04 | 免疫療法の改善のための遺伝子標的の組み合わせ |
| JP2024098698A Pending JP2024111155A (ja) | 2019-02-04 | 2024-06-19 | 免疫療法の改善のための遺伝子標的の組み合わせ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024098698A Pending JP2024111155A (ja) | 2019-02-04 | 2024-06-19 | 免疫療法の改善のための遺伝子標的の組み合わせ |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20200347386A1 (enExample) |
| EP (1) | EP3920942A4 (enExample) |
| JP (2) | JP2022519595A (enExample) |
| KR (1) | KR20210138587A (enExample) |
| CN (1) | CN113396216A (enExample) |
| AU (1) | AU2020217715A1 (enExample) |
| BR (1) | BR112021015170A2 (enExample) |
| CA (1) | CA3128823A1 (enExample) |
| IL (1) | IL285307A (enExample) |
| MX (1) | MX2021009357A (enExample) |
| SG (1) | SG11202108452WA (enExample) |
| WO (1) | WO2020163365A2 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7558563B2 (ja) | 2018-03-15 | 2024-10-01 | ケーエスキュー セラピューティクス， インコーポレイテッド | 免疫療法の改善のための遺伝子調節組成物及び遺伝子調節方法 |
| BR112020018620A2 (pt) | 2018-03-15 | 2020-12-29 | KSQ Therapeutics, Inc. | Composições de regulação gênica e métodos para imunoterapia aprimorada |
| GB202013477D0 (en) * | 2020-08-27 | 2020-10-14 | Quell Therapeutics Ltd | Nucleic acid constructs for expressing polypeptides in cells |
| JP2023539201A (ja) * | 2020-08-28 | 2023-09-13 | ジェネンテック， インコーポレイテッド | 宿主細胞タンパク質のＣＲＩＳＰＲ／Ｃａｓ９マルチプレックスノックアウト |
| WO2022133329A1 (en) * | 2020-12-17 | 2022-06-23 | University Of Florida Research Foundation, Incorporated | Method for programmable control of rna transcript levels with autoregulated crispr-cas13d |
| US12171813B2 (en) | 2021-02-05 | 2024-12-24 | Christiana Care Gene Editing Institute, Inc. | Methods of and compositions for reducing gene expression and/or activity |
| US20220288122A1 (en) * | 2021-03-09 | 2022-09-15 | Crispr Therapeutics Ag | Genetically engineered t cells with ptpn2 knockout have improved functionality and anti-tumor activity |
| WO2023015213A1 (en) * | 2021-08-03 | 2023-02-09 | Spotlight Therapeutics | Ptpn2 specific guide rnas and uses thereof |
| EP4416292A2 (en) | 2021-10-14 | 2024-08-21 | Arsenal Biosciences, Inc. | Immune cells having co-expressed shrnas and logic gate systems |
| US20250352647A1 (en) * | 2021-11-10 | 2025-11-20 | Tsinghua University | Method for enhancing durability of immune cell |
| EP4436967A4 (en) * | 2021-11-23 | 2025-10-22 | Kumquat Biosciences Inc | COMPOUNDS CONTAINING HETEROATOMS AND THEIR USES |
| KR20240130120A (ko) * | 2022-01-05 | 2024-08-28 | 쑤저우 인스티튜트 오브 시스템즈 메디슨 | T 세포 수용체 및 이의 제조 방법과 용도 |
| EP4471128A1 (en) * | 2022-01-29 | 2024-12-04 | Suzhou Grit Biotechnology Co., Ltd. | Modified tumor infiltrating lymphocyte and use thereof |
| US12257304B2 (en) | 2023-03-03 | 2025-03-25 | Arsenal Biosciences, Inc. | Systems targeting PSMA and CA9 |
| WO2025054946A1 (zh) * | 2023-09-15 | 2025-03-20 | 毕诺济(上海)生物技术有限公司 | 敲除Roquin-1和/或Regnase-1基因的肿瘤浸润淋巴细胞及其应用 |
| WO2025082418A1 (zh) * | 2023-10-18 | 2025-04-24 | 苏州沙砾生物科技有限公司 | 一种鉴定靶标的方法及其应用 |
| CN117883382B (zh) * | 2023-11-27 | 2025-02-14 | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | 高效递送疫苗的脂质体载体及脂质体疫苗的制备与用途 |
| WO2025126049A2 (en) * | 2023-12-11 | 2025-06-19 | Crispr Therapeutics Ag | Multiplex gene editing |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7348139B1 (en) * | 2001-04-13 | 2008-03-25 | The Johns Hopkins University School Of Medicine | SOCS-1 gene methylation in cancer |
| CA2574572A1 (en) * | 2004-07-19 | 2006-10-26 | Baylor College Of Medicine | Modulation of cytokine signaling regulators and applications for immunotherapy |
| US20130331294A1 (en) * | 2007-11-09 | 2013-12-12 | Fox Chase Cancer Center | Egfr/nedd9/tgf-beta interactome and methods of use thereof for the identification of agents having efficacy in the treatment of hyperproliferative disorders |
| JPWO2010098429A1 (ja) * | 2009-02-27 | 2012-09-06 | 国立大学法人大阪大学 | 免疫アジュバント組成物、及びその利用 |
| US20150017136A1 (en) * | 2013-07-15 | 2015-01-15 | Cellectis | Methods for engineering allogeneic and highly active t cell for immunotherapy |
| WO2014066137A1 (en) * | 2012-10-22 | 2014-05-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compositions and methods for enhancing cancer immunotherapy |
| KR102301464B1 (ko) * | 2013-06-10 | 2021-09-14 | 다나-파버 캔서 인스티튜트 인크. | 종양 세포에 의한 면역 억제를 감소시키기 위한 방법 및 조성물 |
| CN111218447B (zh) * | 2013-11-07 | 2024-10-11 | 爱迪塔斯医药有限公司 | 使用统治型gRNA的CRISPR相关方法和组合物 |
| AU2015274242A1 (en) * | 2014-06-10 | 2016-12-22 | Monash University | Method of producing leukocytes using PTPN2 inhibition for adoptive cell transfer |
| WO2018148378A1 (en) * | 2017-02-08 | 2018-08-16 | Dana-Farber Cancer Institute, Inc. | Modulating biomarkers to increase tumor immunity and improve the efficiacy of cancer immunotherapy |
| JP2021518162A (ja) * | 2018-03-15 | 2021-08-02 | ケーエスキュー セラピューティクス， インコーポレイテッド | 免疫療法の改善のための遺伝子調節組成物及び遺伝子調節方法 |
-
2020
- 2020-02-04 MX MX2021009357A patent/MX2021009357A/es unknown
- 2020-02-04 JP JP2021545400A patent/JP2022519595A/ja active Pending
- 2020-02-04 AU AU2020217715A patent/AU2020217715A1/en active Pending
- 2020-02-04 KR KR1020217028228A patent/KR20210138587A/ko active Pending
- 2020-02-04 EP EP20751889.5A patent/EP3920942A4/en active Pending
- 2020-02-04 BR BR112021015170-2A patent/BR112021015170A2/pt unknown
- 2020-02-04 WO PCT/US2020/016623 patent/WO2020163365A2/en not_active Ceased
- 2020-02-04 US US16/781,732 patent/US20200347386A1/en active Pending
- 2020-02-04 SG SG11202108452WA patent/SG11202108452WA/en unknown
- 2020-02-04 CA CA3128823A patent/CA3128823A1/en active Pending
- 2020-02-04 CN CN202080012560.2A patent/CN113396216A/zh active Pending
-
2021
- 2021-08-02 IL IL285307A patent/IL285307A/en unknown
-
2024
- 2024-06-19 JP JP2024098698A patent/JP2024111155A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020163365A5 (enExample) | ||
| JP7698828B2 (ja) | Ｒｎａを編集する方法および組成物 | |
| Ehrke-Schulz et al. | CRISPR/Cas9 delivery with one single adenoviral vector devoid of all viral genes | |
| JP6929791B2 (ja) | エピゲノム編集のための組成物および方法 | |
| JPWO2019178422A5 (enExample) | ||
| JP2021534810A (ja) | Ｒｎａを編集する方法および組成物 | |
| Lawrie | Micro RNA s and lymphomagenesis: a functional review | |
| JPWO2019178421A5 (enExample) | ||
| JP2025061660A (ja) | Ｒｎａ誘導型エンドヌクレアーゼを使用するｄｎａ組み込みのための改善された方法 | |
| KR20230146127A (ko) | 암 면역요법을 위한 crispr-cpf1-관련 방법, 조성물 및 구성성분 | |
| CN110139675A (zh) | 用具有工程化稳定的内源性foxp3基因表达的cd4 t细胞治疗自身免疫疾病的方法 | |
| JP2022509017A (ja) | 抗ｐｔｋ７免疫細胞癌療法 | |
| JP2024133347A (ja) | Ｒｎａ誘導型エンドヌクレアーゼを使用したｄｎａ構築物の組み込みプロセスの向上 | |
| JP2021502077A5 (enExample) | ||
| JPWO2019178420A5 (enExample) | ||
| AU2021369494A9 (en) | Safe harbor loci | |
| WO2022012531A1 (zh) | 一种经修饰的免疫细胞的制备方法 | |
| JPWO2020176740A5 (enExample) | ||
| CN108495640A (zh) | 短发夹rna(shrna734)及其用于阳性选择和消除遗传修饰的细胞的用途 | |
| EP4352226A1 (en) | Peptide nucleic acids for spatiotemporal control of crispr-cas binding | |
| CN117460541A (zh) | 增强用于细胞疗法的分离的细胞治疗功效的方法 | |
| JP2025049296A (ja) | 高度にコンパクトな多入力論理ゲートをコードする核酸ベクターを使用して疾患を処置する方法 | |
| JP2025517469A (ja) | 増殖依存性の遺伝子発現を示す、核酸で改変された生体細胞 | |
| KR20230102519A (ko) | 특이적 전달을 위한 핵산 나노구조 복합체 및 그 용도 | |
| WO2022015956A1 (en) | Improved process for dna integration using rna-guided endonucleases |